Cartesian Therapeutics, Inc. RNAC 深 沪
等待开盘 08-10 09:30:00 美东时间
8.85
+0.090
+1.03%
华盛通- 最 高8.945
- 今 开8.88
- 成交量 8.05万股
- 最 低 7.77
- 昨 收 8.76
- 总市值 0
- 52周最高 11.77
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 5.60
- 委 比 0.00%
- 总股本 --
- 历史最高 41.87
- 量 比 0.60
- 振 幅 13.41%
- 历史最低 0.4711
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Insights into Cartesian Therapeutics Q4 Earnings
Cartesian Therapeutics (NASDAQ:RNAC) just disclosed its Q4 earnings on Monday, ...
03-09 19:44
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.
01-07 02:42
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.
2025-11-15 02:02
从实验室到智能工厂：AI制药的黄金十年
原标题：从实验室到智能工厂：AI制药的黄金十年 英矽智能的生成式AI平台仅用18个月完成从靶点发现到候选药物设计，其抗纤维化新药INS018_055已进入Ⅱ期...
2025-08-15 16:37
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $45 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $45 price target.
2024-09-13 18:28
Cartesian Therapeutics Has Dosed The First Patient In Its Phase 1 Trial Of Descartes-15, The Company's Next-generation Autologous Anti-B Cell Maturation Antigen mRNA-Engineered Chimeric Antigen Receptor T-cell Therapy
The Phase 1 dose escalation trial (NCT06304636) will assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma. Following the Phase 1 dose escalation trial, the Company expects to subsequently assess Descartes-15 in autoimmune indications.
2024-09-03 19:04
